ZEO ScientifiX, Inc. has reported significant revenue growth for the three months and six months ending April 30, 2026. The company recorded revenues of $2,581,000 for the latest quarter, a notable increase compared to $1,149,000 during the same period in 2025. This growth translates to a 124.6% increase attributed primarily to heightened sales of its allogenic biologic products.
For the six-month period ending April 30, 2026, ZEO ScientifiX reported total revenues of $4,027,000, up from $2,239,000 in the previous year, marking a year-over-year increase of 79.9%.
The surge in revenues is linked to a broader acceptance and demand for the company’s allogenic biologic products. The state of Florida has shown increased activity in stem-cell-focused biologics, contributing to this growth. Expanded adoption of ZEO's therapeutics by physicians has also played a crucial role, alongside concerted efforts to raise awareness through educational initiatives, conferences, and other commercial strategies.
While ZEO ScientifiX experienced substantial revenue growth, the company reported a net loss of approximately $1.0 million for the six months ended April 30, 2026, although this represented a substantial improvement from a net loss of approximately $2.6 million during the same period in 2025. The company maintained strong gross margins of around 80%, reflecting its operational efficiency amid market challenges.
Ian Bothwell, CEO of ZEO ScientifiX, remarked on the company's progress, noting the importance of the growth momentum as it caters to the needs of clinicians seeking reliable partners in regenerative medicine. The company is committed to enhancing research, safety, and quality in further developing its offerings.
ZEO ScientifiX reported revenues of $2,581,000 for the three months ended April 30, 2026, compared to $1,149,000 for the same period in 2025. For the six months ended April 30, 2026, revenues were $4,027,000, an increase from $2,239,000 in 2025.
The revenue growth of 124.6% for the quarter and 79.9% for the six months was primarily attributed to increases in sales associated with the company's allogenic biologic products, alongside growing physician adoption and broader awareness of ZEO's technologies.
ZEO ScientifiX maintained gross margins of approximately 80.0% during both the six-month periods ended April 30, 2026, and 2025, indicating consistent cost management alongside revenue growth.
The company reported a net loss of approximately $1.0 million for the six months ended April 30, 2026, which is a decrease from a net loss of approximately $2.6 million for the same period in 2025.
ZEO ScientifiX is focusing on increasing physician education, attending conferences, and implementing commercial initiatives to enhance awareness and strengthen relationships, which may contribute to its market presence.
ZEO ScientifiX is listed under the ticker symbol OTCQB:ZEOX.
ZEO ScientifiX, Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and manufacturing of regenerative biologics.
Yes, the forward-looking statements made by ZEO ScientifiX involve known and unknown risks and uncertainties, meaning actual results may differ from expectations.